Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Ozempic label provides placebo-controlled adverse reaction rates for common events (5%) dominated by GI symptoms (dose-related increases in nausea, vomiting, diarrhoea, constipation/abdominal pain)
If youre suffering, check with your doctor If going on a GLP-1 suppresses your appetite to the point that youre not interested in eating at all, or if youre vomiting frequently or severely constipated, reach out to your provider: Your GLP-1 dosing may need to be lowered
Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) demonstrated significant reductions in major adverse cardiovascular events, while others showed cardiovascular safety without superiority
Ask a pharmacist or healthcare provider for device-specific technique help
